Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425758 | 1.00 | P2RX3 (0.34) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL22425931 | 0.89 | TYK2 (0.32) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL22425928 | 0.88 | P2RX3 (0.36) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL22425745 | 0.88 | P2RX3 (0.36) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL22425927 | 0.88 | P2RX3 (0.36) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL28662214 | 0.88 | ABL1 (0.35) | P2RX3TYK2PDE4D | |
| SCHEMBL22425760 | 0.87 | P2RX3 (0.36) | P2RX3TYK2PDE4DMALT1 | |
| SCHEMBL24500229 | 0.84 | P2RX3 (0.31) | P2RX3MALT1 | |
| SCHEMBL22426025 | 0.82 | MALT1 (0.33) | P2RX3MALT1 | |
| SCHEMBL22411790 | 0.81 | P2RX3 (0.32) | P2RX3MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| CN-113811534-A | TYK2 inhibitors and uses thereof | 埃斯克疗法股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | P2RX3 3708/4885TYK2 1/4885PDE4D 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.